The proportion of younger patients undergoing total knee arthroplasty (TKA) is increasing and predictions state that the 45–54 age group will be the fastest growing group by 2030. We aim to collate data across studies to assess functional outcomes following total knee replacement in patients under 55 years of age. Secondary outcomes include implant survival and complications will also be reviewed. The search identified 980 studies for title and abstract review. 43 full-texts were then assessed. 13 studies underwent quality assessment and data extraction from them. PRISMA guidelines were followed throughout. Outcomes extracted included pre- and post-operative functional scores, range of motion (ROM) and patient satisfaction. Clinical complications and survival were also recorded. Across 13 studies we were able to demonstrate 54-point improvement in clinical Knee Society Score and a 2.9° improvement in range of motion. Satisfaction rate was 85.5%. Revision rate was 5.4% across 1323 TKAs. Risk of revision for aseptic loosening was 0.37% per year. Total knee arthroplasty is an excellent treatment option for the young osteoarthritic knee with a >50% improvement in functional knee scores. Satisfaction is high and the revision rate remains under 1% per year.
The optimal treatment for isolated patello-femoral arthritis is unclear. Patello-femoral arthroplasty (PFA) may offer superior knee function in isolated patello-femoral osteoarthritis compare to TKA. The literature is controversial for patient outcomes in PFA. Some reports showed improved outcomes while others were disappointing. We assessed our outcomes to try to identify causes for poor outcomes. The Trent Arthroplasty was established in 1990 to collect prospective data on knee arthroplasty surgery. Data is entered by surgeons at the time of surgery, with patient consent. PFA constitute less than 1% of the arthroplasties performed in this region. Patients were sent self-administered outcome forms 1 year post-op. Re-operation and revision procedures were reported. 334 PFA have been registered from 17 hospitals. 79% were female patients with 43% of the patients aged 55 years or less, suggesting dysplasia as the cause of their osteoarthritis. Age range 28–94 yrs (SD 11.8 yrs). The implants were Stryker Avon 236, Corin Leicester 47, Link Lubinus 24, Smith & Nephew Journey 10, DePuy LCS 7, Wright FPV 2, other 8.Introduction
Methods
Only 0.8% of arthroplasties registered on the National Joint Registry in 2006 are patello-femoral. The Leicester patello-femoral replacement (Corin) has been in use for over 10 years with satisfactory initial results. The indication for use is isolated patello-femoral osteoarthritis with the theoretical benefits of bone preservation, maintenance of normal knee mechanics and easy revision. The implant was only available in one size and the femoral component was uncemented. We reviewed 49 patients managed with this prosthesis with a median follow up of 10 years (range 4-16). The mean age of the patients at time of surgery was 64. 62 arthroplasties were performed.51 were in females and 11 in males giving a 5:1 ratio. Thirteen patients had bilateral procedures. Thirty-nine revisions (62.9%) were performed for progressive tibio-femoral arthritis or prosthetic failure. Mean time to revision was 5 years 3 months. The knees were revised to total knee replacements without the need for stems, wedges or constraint. The unrevised knees had a mean survivorship of 8 years 6 months with a range of 4-14 years. The mean Oxford score for these surviving implants was 22.5. Results of other implants from the literature included the Avon prosthesis with 80% satisfaction rate at 5 years and the Lubinus with 45% satisfaction rate at 7.5 years. The Leicester device showed a pattern of progressive failure with up to 40% revision at 5 years. However those with surviving implants were reasonably happy as shown by the Oxford scores. We concluded that patello-femoral replacement has a role though this is not as well defined as TKR or even UKR. We posed the question as to whether these results were due to poor patient selection or design failings of the Leicester prosthesis. This prosthesis has been successful at reducing pain and improving function and may have been more successful with more sizes of implant, better instrumentation and more rigid patient selection.
NICE published the guidelines ‘Selection of prostheses for primary hip replacement’ in 2000. Essentially these guidelines made two recommendations: firstly to use prostheses which had attained the ‘10 year benchmark’ of a revision rate of 10% or less at 10 years, or had a minimum of three years revision rate experience that was on target to reach this benchmark; and secondly to use cemented hip prostheses to the exclusion of uncemented and hybrid prostheses. The information from the Trent Regional Arthroplasty Study (TRAS) has been used to retrospectively examine the types of hip prostheses used from 1990 – 2005, and assess the impact that the NICE guidelines have had on orthopaedic practice. This study revealed that the percentage of prostheses used which attained the ‘ten year benchmark’ has increased since the guidelines were published. In 2001, of the ten cups, which constituted 80% of the acetabular components used, only three attained this NICE benchmark, but by 2005 this number had risen to eight. Similarly in 2001, of the eight stems, which constituted almost 80% of the femoral components used, only five attained this NICE benchmark. In 2005 seven out of these eight stems had attained the minimum standard. However contrary to the recommendation made by NICE in 2000, to use cemented prostheses, the results indicate the use of uncemented prostheses has trebled (from 6.7% to 19.2%, n= 137 and 632 respectively), and the use of hybrid prostheses has more than doubled (from 8.8% to 22% of all prostheses, n= 181 and 722 respectively) since the guidelines were published. Therefore the recommendations made by NICE are not being followed, which calls the value of NICE guidelines into question.
